SCHEMBL2591986

SCHEMBL2591986

CC(C)(C)OC(=O)N1c2ccc(Br)cc2Sc2cc(Br)cc(C(F)(F)F)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 5/20 0.47
▸ RBP4 P02753 1/20 0.35
▸ USP30 Q70CQ3 2/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ NOX1 Q9Y5S8 1/20 0.33
▸ BACE1 P56817 2/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ GPR119 Q8TDV5 1/20 0.32
▸ AR P10275 2/20 0.31
▸ HCAR1 Q9BXC0 1/20 0.31
▸ ABHD6 Q9BV23 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ ALOX12 P18054 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ CTDSP1 Q9GZU7 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ SNCA P37840 1/20 0.31
▸ RORC P51449 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27892048 0.90 BCHE (0.62) BCHENOX1SLC6A3MEN1MAPT
SCHEMBL9933040 0.87 BCHE (0.40) BCHERBP4GPR119ARABHD6
SCHEMBL12273366 0.86 BCHE (0.49) BCHERBP4USP30CDK1NOX1
SCHEMBL2587116 0.85 BCHE (0.38) BCHEMEN1KMT2ATDP1
SCHEMBL31022783 0.84 BCHE (0.64) BCHERBP4USP30CDK1NOX1
SCHEMBL12813131 0.84 BCHE (0.64) BCHERBP4USP30CDK1NOX1
SCHEMBL15908923 0.81 BCHE (0.46) BCHEUSP30CDK1NOX1BACE1
SCHEMBL19744454 0.81 BCHE (0.41) BCHEMEN1MAPTALOX12KMT2A
SCHEMBL12273405 0.79 BCHE (0.44) BCHEUSP30CDK1NOX1BACE1
SCHEMBL2594780 0.77 PDK2 (0.46) BCHEGPR119MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585073-B1 ANTIVIRAL COMPOUNDS PROSETTA ANTIVIRAL INC (US) 2016-04-27 — — EP disclosed
US-8785434-B2 Antiviral compounds PROSETTA ANTIVIRAL INC. (US) 2014-07-22 — — US disclosed
EP-2585073-A1 ANTIVIRAL COMPOUNDS Prostetta Antiviral Inc. (US) 2013-05-01 — — EP disclosed
US-20120157435-A1 Antiviral Compounds PROSETTA ANTIVIRAL INC. (US) 2012-06-21 — — US disclosed
WO-2011137447-A1 ANTIVIRAL COMPOUNDS PROSTETTA ANTIVIRAL INC. (US) 2011-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157435-A1 Antiviral Compounds MAVS, ZC3HAV1, EIF2AK2 BCHE 1570/4885RBP4 452/4885USP30 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback